London, 20 November 2026 – Established drugmakers are reassessing their relationship with artificial-intelligence developers as well-funded technology groups move deeper into medicine discovery. Industry discussions reported on 20 November followed Isomorphic Labs’ US$5 billion Series C announcement on 17 November, bringing the scale of AI funding into sharp focus at the week’s Jefferies Global Healthcare Conference in London.
For Asian healthcare businesses and investors, the issue is not whether larger funding rounds prove better medicines. They can increase competition for research talent, partnerships and investment capital, while new AI developers may work alongside pharmaceutical companies and pursue their own pipelines. The commercial question is how those relationships divide expertise, development risk and eventual economic value.
Unlock the Full Article
This article is exclusive to The Ledger Asia Subsribers / PAID members.
Already have an account? Log in here